MAPK8 and non-small cell lung carcinoma: We found that vandetanib treatment reduced the protein expression levels of both p-ERK and p-JNK in A549 and H1795 cells (Supplement Figure S3A) but did not alter the morphology of these two cell lines (Supplement Figure S3B), suggesting that vandetanib-induced inhibition of p-JNK is a general effect among NSCLC cells.